Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Income from Continuing Operations (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Income from Continuing Operations readings, the most recent being 8967000.0 for Q4 2024.

  • On a quarterly basis, Income from Continuing Operations fell 44.82% to 8967000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 30927000.0, a 52.79% decrease, with the full-year FY2025 number at 28576000.0, up 7.6% from a year prior.
  • Income from Continuing Operations hit 8967000.0 in Q4 2024 for Unicycive Therapeutics, down from 5850000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 3537000.0 in Q1 2022 to a low of 9155000.0 in Q1 2024.
  • Median Income from Continuing Operations over the past 3 years was 5643000.0 (2022), compared with a mean of 5768833.33.
  • The widest YoY moves for Income from Continuing Operations: up 2.11% in 2024, down 117.98% in 2024.
  • Unicycive Therapeutics' Income from Continuing Operations stood at 5328000.0 in 2022, then dropped by 16.22% to 6192000.0 in 2023, then plummeted by 44.82% to 8967000.0 in 2024.
  • The last three reported values for Income from Continuing Operations were 8967000.0 (Q4 2024), 5850000.0 (Q3 2024), and 6955000.0 (Q2 2024) per Business Quant data.